Lonza

Attending ARM on the Med 2025 in Rome this week? Behnam Ahmadian Baghbaderani, our Vice President, Global Head of Commercial and Program Management, will be moderating a panel on Day 1 (April 15): Commercializing ATMPs: Moving from Innovation to Market Success. Thrilled to be moderating a dynamic panel alongside some truly esteemed speakers, Shankar Musunuri, PhD, MBA, Kinnari Patel, PharmD, MBA, and Rebecca Poehnelt. Don't miss out. #CGMed25 #LonzaCGT #Celltherapy #Genetherapy

Will you be at Cell Culture Engineering XIX 2025 in Tucson, Arizona? Our expert R&D team will be on-site, sharing the latest scientific advancements in optimizing industrial bioproduction. As the biopharmaceutical landscape continues to evolve, we remain committed to developing innovative solutions that ensure we stay one step ahead of your next challenge. 🔬 Join us at our sessions: ·      Lunch & Learn - Advancing Multispecific Molecule Manufacturing through Optimized Vector Design and CHO Cell Line Development hosted by Stephen Jaffe and Arina David Alfred  29th April | 1 pm – 1.30 pm ·      Lightning talk - Machine-learning assisted clone selection yields improved clone titers in intensified cell culture processes by Brandon Downey ·      Poster - Long-read sequencing and multiomics integration to enable precision cell line engineering by Mounika Reddy  ·      Poster - Omics profiling of recombinant CHO clones in Lonza´s fed-batch platform process by Sandeep Ranpura Please refer to the conference program for more details here: https://lnkd.in/ecqUCRej We look forward to seeing you in Tucson! #Lonza #LonzaExpressionTechnologies #IntegratedBiologics  

We have just joined CMAC, a world leading center for medicines manufacturing research, to enhance our service offering for particle technologies and drug product development and manufacture. Through our membership, Lonza will gain access to CMAC’s unique network, which advances Chemistry, Manufacturing and Control technologies, implements digitalization strategies and develops innovative continuous processing and crystallization solutions for active pharmaceutical ingredients and drug product technologies. Read more: https://lnkd.in/gZhcfK5z #Lonza #CDMO #PharmaceuticalManufacturing

Join us at Festival of Biologics in San Diego, California. Don't miss our great line-up of speakers this year: 🔷 Wednesday, 23 April, 15:40 Formulation Strategies for Highly Concentrated Biologics Eddy Berthier More info: https://lnkd.in/e9q5fZCD 🔷 Wednesday, 23 April, 16:50 Building Strong Bridges: Maximizing the use of expressed drug candidate material to compress timelines and streamline the path to first-in-human studies Raymond Donninger More info: https://lnkd.in/e_8jE8zJ 🔷 Wednesday, 23 April, 12:30 Commercial Biomanufacturing: Evolution, Adaptation, and the Survival of the Fittest Marco Mirata

Join Lonza’s Jens Schmidt on 15th April 2025 at the Organic Chemistry Colloquium, University of Hamburg, as he presents: “From Flasks to Factories – Translating Organic Chemistry into Industrial Reality.” Jens will dive into how Lonza leverages AI-enabled route scouting, high-throughput experimentation (HTE) and model-based experimental design to enable faster, smarter, and more sustainable process development, bridging innovation from bench to commercial scale. #Lonza #CDMO #MakingtheMedicinesofTomorrow

"New opportunities for mRNA technology are emerging rapidly, expanding into applications well beyond vaccines. This is demonstrated by the over 300 active studies of mRNA therapeutics to treat various diseases. One of the most exciting areas is gene editing, where mRNA is advancing cell and gene therapies. This includes in vivo gene editing for metabolic and genetic diseases and CAR-T therapies." Sönke Stocker, Executive Director of Innovation and Strategic Growth for mRNA at Lonza, gave his thoughts on some of the new opportunities emerging for mRNA technology in an article by Pharma's Almanac. Read the full article here: https://lnkd.in/eKzhv5Mz #Lonza #PharmaceuticalManufacturing #mRNA #Innovation

"The combination of these technology platforms makes sense. With our small molecules technology platform we focus on complex, difficult to manufacture molecules, amongst other drug-linkers, providing our CDMO services primarily to leading innovators in our space. With our bioconjugation technology platform, we perform the conjugation step to link the drug-linker to the antibody. What excites me about the new One Lonza strategy and new operating model is that we can offer our customers fully integrated services including antibody development and manufacturing as well as fill & finish services, both technology platforms of our Integrated Biologics business platform." Christian Seufert, Head of Advanced Synthesis at Lonza, recently spoke to Pharma Manufacturing about Lonza's new business platform setup, and the exciting synergies of the Advanced Synthesis platform. Read the full interview here: https://lnkd.in/gE67CuGr #Lonza #CDMO #PharmaceuticalManufacturing #Pharma #Biotechnology

Our team is heading to Rome next week for the Alliance for Regenerative Medicine (ARM)'s 2025 Cell & Gene Meeting on the Med. Behnam Ahmadian Baghbaderani, our Vice President, Global Head of Commercial and Program Management, will be moderating a panel on Day 1 (April 15): Commercializing ATMPs: Moving from Innovation to Market Success Don’t miss this session if you’re attending! We’ll also have a private meeting room on-site. Use the partnering system to connect with Jules Foster, Andreas Junger and Mark Langtry and schedule a meeting in advance: https://lnkd.in/eayDAcKp We’re looking forward to inspiring conversations, meeting industry leaders, and discussing our future collaboration opportunities. #CellTherapy #GeneTherapy #CGMED25 #Lonza

We are proud to have been named one of LinkedIn's Top Companies in Switzerland for 2025. Our people sit at the heart of our business, and we strive to give our colleagues the best possible professional experience. Across our global network, we are committed to creating an inclusive environment where people feel they belong and are empowered to bring their best. The LinkedIn Top Companies list recognizes the top 25 employers in Switzerland, by looking at the level of support given to professional development, as well as the advancement of employees within the company. Find the full list here: https://lnkd.in/dEsdP3J3 #LinkedInTopCompanies #Lonza #CDMO #Opportunities #CareerGrowth

We have just announced a collaboration with Ethris to develop room-temperature stable, spray-dried formulations of mRNA-based vaccine candidates that offer a promising approach to combat respiratory diseases. We will provide spray-drying and particle engineering for vaccine candidates based on Ethris’ stabilized non-immunogenic mRNA (SNIM® RNA) and stabilized lipid nanoparticles (SNaP LNP) platform at our Bend (US) site, which specializes in addressing bioavailability challenges and modulating pharmacokinetics to meet target product profiles. Lonza’s development expertise enables access to ideal properties for delivery to the respiratory tract alongside physical stability, while preserving the activity of the mRNA encapsulated within an LNP. Read more here: https://lnkd.in/d2mVi5-T #Lonza #CDMO #PharmaceuticalManufacturing #mRNA